ROSSARI
making you more competitive

July 18, 2026

DCS-CRD **BSE Limited** First Floor, New Trade Wing Rotunda Building, Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400001 Fax No.2272 3121/2037/2039 Stock Code: 543213	Listing Compliance **National Stock Exchange of India Limited** Exchange Plaza, 5th Floor Plot No. C/1, 'G' Block, Bandra- Kurla Complex Bandra East Mumbai 400051 Fax No.2659 8237/8238 Stock Code: ROSSARI

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on Saturday, July 18, 2026

Ref.: Compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With regards to the captioned matter and in compliance with the Securities and Exchange Board of India ("**SEBI**") (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "**Listing Regulations**"), as amended, this is to inform that at the meeting of the Board of Directors of the Company ("**the Board**") which commenced at 12:00 noon and concluded at 02:00 p.m. today i.e. Saturday, July 18, 2026, the Board have inter alia approved the following:

1. **Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026**

   Copy of Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026 are enclosed herewith.

   The aforesaid results were reviewed by the Audit Committee and subsequently, approved and taken on record by the Board of Directors of the Company. We would further like to inform that the Statutory Auditors of the Company have subjected the aforesaid results to **"Limited Review"** and the same is enclosed herewith.

2. **Grant of Options under Rossari Employee Stock Option Plan - 2019.**

   Pursuant to Regulation 30 of the Listing Regulations and ratification of the Rossari Employee Stock Option Plan - 2019 (**"ESOP 2019"**) by the Members of the Company on April 17, 2021, the Board has approved grant of 4000 Stock Options under ESOP 2019.

   Further, detailed intimation as per Regulation 30 of the Listing Regulations for Grant of Options under ESOP 2019, are enclosed as **Annexure - I**.

ROSSARI BIOTECH LIMITED MUMBAI

3. **Allotment of Equity Shares under the Rossari Employee Option Plan - 2019**

With reference to the in-principle approval received from BSE Limited Letter Ref. No. DCS/FL/MJ/ESOP-IP/1257/2021-22 dated May 25, 2021 and National Stock Exchange of India Limited Letter Ref. No. NSE/LIST/26888 dated May 28, 2021 for issue and allotment of 1500000 Equity Shares of Rs. 2/- each to be issued under ESOP 2019, the Board approved the allotment of 2500 Equity Shares of Rs. 2/- each fully paid to the grantees on exercise of the options granted to them pursuant to ESOP 2019.

Said equity shares shall rank pari passu, in all respects with the existing equity shares of the Company. Consequent, to the allotment of the aforesaid equity shares, the issued and the paid-up equity share capital of the Company stands increased to Rs. 11,07,88,232 consisting of 55394116 Equity Shares of Rs. 2/- each.

Details as required under the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 are enclosed as **Annexure - II.**

4. **Transfer of 100% shareholding of Rossari International Limited Company to Rossari (Singapore) Pte. Ltd.**

The Board has approved the transfer of the Company's 100% shareholding in Rossari International Limited Company (RILC), a wholly owned subsidiary of the Company, to Rossari (Singapore) Pte. Ltd. (Rossari Singapore), which is also a wholly owned subsidiary of the Company.

The proposed transfer is undertaken as part of an internal group restructuring exercise aimed at bringing all overseas subsidiaries of the Company under a single, existing overseas investment subsidiary, thereby establishing a common holding platform. The restructuring is intended to simplify overseas regulatory reporting into a single reporting line.

The transaction is subject to: (i) Execution of a Share Purchase Agreement between the relevant parties; and (ii) Receipt of requisite approvals from the relevant authorities in the Kingdom of Saudi Arabia.

On completion of the transaction, RILC, shall become wholly owned subsidiary of Rossari Singapore and a step-down wholly owned subsidiary of the Company. As the transaction is a transfer of shareholding between holding and wholly owned subsidiary of the Company, there is no change in the ultimate beneficial ownership of RILC, and the transaction is not expected to have any material impact on the Company's consolidated financial position or operations.

Details required pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed as **Annexure - III**.

The same may please be taken on record and suitably disseminated to all concerned.

Thanking You,

Yours Sincerely,
For Rossari Biotech Limited

Parul Gupta Digitally signed by Parul Gupta Date: 2026.07.18 16:24:15 +05'30'

ROSSARI BIOTECH LIMITED MUMBAI

Parul Gupta
Company Secretary & Head - Legal
Membership No.: A38895

Encl.: as above

ROSSARI® making you more competitive

Annexure-I

Detailed intimation as per Regulation 30 of the Listing Regulations

Sr. No.	Particulars	Details
1.	Brief details of options granted	Grant of 4000 Options to eligible employees.
2.	Whether the scheme is in terms of SEBI (Share based Employee Benefits and Sweat Equity) Regulations, 2021 (if applicable)	Yes, the Rossari Employee Stock Option Plan - 2019 (ESOP 2019) has been formulated and adopted by the Company in terms of the Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014.
3.	Total number of shares covered by these options	4000 Equity Shares of the face value Rs. 2/- each (As per terms, each Option will be converted into one Equity Share of the Company).
4.	Pricing Formula/ Exercise Price	As per the ESOP 2019, the exercise price of the Options will be decided by the Board/Nomination & Remuneration Committee. The exercise price determined is Rs. 531 per Option.
5.	Options Vested/ Vesting Schedule	The Options shall vest as under: – At the end of 1st year from the grant date - 20% of options granted. – At the end of 2nd year from the grant date - 20% of options granted. – At the end of 3rd year from the grant date - 20% of options granted. – At the end of 4th year from the grant date - 40% of options granted.
6.	Time within which option may be exercised	All vested Options shall be exercisable within 5 years from the date of vesting of the respective Options or such other period as may be determined by the Nomination and Remuneration Committee from time to time.
7.	Options exercised	Not Applicable
8.	Money realized by exercise of Options	Not Applicable
9.	The total number of Shares arising as a result of exercise of Option	4000 Equity Shares of face value Rs. 2/- each will arise deeming all granted options are vested and exercised.
10.	Options lapsed	Not Applicable
11.	Variation of terms of Options	Not Applicable

ROSSARI BIOTECH LIMITED MUMBAI

Sr. No.	Particulars	Details
12.	Brief details of significant terms	The ESOP 2019 is administered by the Nomination and Remuneration Committee of the Board. The grant of Options by the Nomination and Remuneration Committee/ the Board is based upon the eligibility criteria as per ESOP 2019. The granted Options, once vested shall entitle the Option holder to acquire equal number of Equity Shares, upon payment of exercise price and applicable taxes in accordance with terms and conditions of the ESOP 2019. The Exercise Price of the Options granted to an Eligible Employee shall be determined by the Nomination and Remuneration Committee/ the Board, subject to conforming to applicable accounting policies. Provided, however, the Exercise Price shall in no event be less than the face value of the Shares.
13.	Subsequent changes or cancellation or exercise of such Options	Not Applicable
14.	Diluted earnings per share pursuant to the issue of equity shares on exercise of Options	Not Applicable

ROSSARI BIOTECH LIMITED MUMBAI

ROSSARI
making you more competitive

Annexure-II

Disclosure pursuant to Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021

Sr. No.	Particular	Disclosure - Rossari Employee Stock Option Plan - 2019
1.	Company name and address of Registered Office	Rossari Biotech Limited CIN: L24100MH2009PLC194818 Registered Office: Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai - 400079.
2.	Name of the Stock Exchanges on which the Company's shares are listed	1. BSE Limited (BSE) 2. National Stock Exchange of India Limited (NSE)
3.	Filing date of the statement referred in regulation 10(b) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 with Stock Exchange	Filing date of statement is as follows: 1. BSE Limited: May 20, 2021 2. National Stock Exchange of India Limited: May 25, 2021
4.	Filing No., if any	BSE: 129899 NSE: 26888
5.	Title of the Scheme pursuant to which shares are issued, if any	Rossari Employee Stock Option Plan - 2019
6.	Kind of security to be listed	Equity Shares
7.	Par Value of the shares	Rs. 2/-
8.	Date of Issue of shares	July 18, 2026
9.	Number of shares issued	2500 Shares
10.	Share Certificate No., if applicable	Not applicable
11.	Distinctive Number of the shares, if applicable	55391617 to 55394116
12.	ISIN of the shares if issued in Demat	INE02A801020
13.	Exercise price per share	Rs. 425/-
14.	Premium per share	Rs. 423/-
15.	Total Issued shares after this issue	55394116 Shares
16.	Total Issued share capital after this issue	Rs. 11,07,88,232
17.	Details of any lock-in on the shares	Not applicable
18.	Date of expiry of lock-in	Not applicable
19.	Whether shares identical in all respects to existing shares, if not, when will they become identical	All equity shares allotted pursuant to exercise of stock options shall rank pari-passu with the existing equity shares of the Company
20.	Details of listing fees, if applicable	Not applicable

ROSSARI BIOTECH LIMITED MUMBAI

Annexure -III

Details required pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Sr. No.	Particulars	Details
1.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year;	The amount and percentage of the turnover and net worth contributed by Rossari International Limited Company (RILC) as on March 31, 2026 is as below: Turnover: Rs. 0.22 crores (0.009%) Net worth: Rs. 22.425 crores (1.68%)
2.	Date on which the agreement for sale has been entered into	Share Purchase Agreement is yet to be executed.
3.	The expected date of completion of sale/disposal	Expected to complete by March 31, 2027, subject to receipt of requisite approvals from the relevant authorities in the Kingdom of Saudi Arabia.
4.	Consideration received from such sale/disposal;	Consideration proposed to be received from the sale of 9,000 shares of face value SAR 1,000/- each of RILC by the Company to Rossari (Singapore) Pte. Ltd. in one or more tranches is ~ Rs. 24 Crores.
5.	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof	Rossari (Singapore) Pte. Ltd. (Rossari Singapore), is a wholly owned subsidiary of the Company incorporated on December 18, 2025. Except as mentioned above, Rossari Singapore does not belong to the Promoter/Promoter Group of the Company.
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length	Rossari Singapore is a wholly owned subsidiary of the Company. Aforesaid transaction falls within the ambit of Related Party Transaction and will be done on arm's length basis.
7.	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations	Not Applicable

Sr. No.	Particulars	Details
8.	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not Applicable

****

Walker Chandiok & Co LLP
42nd Floor,
Building Commerz III,
International Business Park,
Oberoi Garden City,
Off Western Express Highway,
Goregaon (East),
Mumbai-400063
T +91 22 6626 2699

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Rossari Biotech Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of **Rossari Biotech Limited** ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), its associate and joint venture (refer Annexure 1 for the list of subsidiaries, associate and joint venture included in the Statement) for the quarter ended **30 June 2026**, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

WALKER CHANDIOK & CO LLP
MUMBAI
CHARTERED ACCOUNTANTS

5. We did not review the interim financial results of five subsidiaries included in the Statement, whose financial results reflect total revenues of ₹ 5,570.67 million, total net profit after tax of ₹ 83.71 million, total comprehensive income of ₹ 84.20 million for the quarter ended on 30 June 2026, as considered in the Statement. The Statement also includes the Group's share of net profit after tax of ₹ 3.70 million and total comprehensive income of ₹ 3.70 million for the quarter ended on 30 June 2026, as considered in the Statement, in respect of an associate, whose interim financial results have not been reviewed by us. These interim financial result have been reviewed by other auditors whose review report have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and an associate is based solely on the review reports of such other auditors and the procedures performed by us as stated in paragraph 3 above.

   Further, of these subsidiaries, 1 subsidiary company is located outside India, whose interim financial results have been prepared in accordance with accounting principles generally accepted in its country of domicile and which have been reviewed by other auditor under generally accepted auditing standards applicable therein. The Holding Company's management has converted the financial results of such subsidiary from accounting principles generally accepted in its country to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion, in so far as it relates to the balances and affairs of this subsidiary is based on the review report of other auditor and the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

   Our conclusion is not modified in respect of these matters with respect to our reliance on the work done by and the reports of the other auditors.

6. The Statement includes the interim financial information of five subsidiaries, which have not been reviewed by their auditors, whose interim financial information reflects total revenues of ₹ 18.10 million, net loss after tax of ₹ (8.46) million, total comprehensive loss of ₹ (8.46) million for the quarter ended 30 June 2026, as considered in the Statement. The Statement also includes the Group's share of net profit after tax of ₹ 0.87 million and total comprehensive income of ₹ 0.87 million for the quarter ended on 30 June 2026, in respect of a joint venture, based on their interim financial information, which have not been reviewed by their auditor, and have been furnished to us by the Holding Company's management. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and a joint venture, are based solely on such unreviewed interim financial information. According to the information and explanations given to us by the management, these interim financial information are not material to the Group.

   Our conclusion is not modified in respect of this matter with respect to our reliance on the financial results certified by the Board of Directors.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

BdShetty

Bharat Shetty
Partner
Membership No. 106815

UDIN: 26106815UHYNKH9410

Place: Mumbai
Date: 18 July 2026

Annexure 1

List of entities included in the Statement

Sr. No.	Particulars
	Subsidiaries
1	Buzil Rossari Private Limited
2	Rossari Consumer Products Private Limited
3	Unitop Chemicals Private Limited
4	Tristar Intermediates Private Limited
5	Rossari Bangladesh Limited (under liquidation)
6	Rossari Global FZCO (Formerly known as Rossari Global DMCC)
7	Rossari International Company Limited
8	Rossari (Singapore) PTE. Ltd. (Incorporated on 18 December 2025)
	Step down subsidiaries
1	Rossari Biotech Trading FZE
2	Unistar Thai Co. Ltd
	Joint Venture
1	Hextar Unitop SDN BHD (Joint venture of Unitop Chemicals Private Limited)
	Associate
1	Romakk Chemicals Private Limited

WALKER CHANDIOK & Co LLP MUMBAI CHARTERED ACCOUNTANTS

BS

ROSSARI BIOTECH LIMITED

(An ISO 9001:2015, 14001:2015 & 45001:2018 Certified Company)

Regd. Office : Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (W) Mumbai – 400079
T +91-22-6123 3800 F +91-22- 25796982 E info@rossari.com W www.rossari.com CIN: L24100MH2009PLC194818

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026

Rs. In million

	Particulars	Quarter ended			Year Ended
		30th June, 2026	31st March, 2026	30th June, 2025	31st March, 2026
		Unaudited	Refer Note 5	Unaudited	Audited
I	**INCOME**				
	Revenue from operations	6,972.00	6,848.62	5,437.16	23,963.65
	Other Income	31.87	190.65	12.00	223.78
	Total Income	**7,003.87**	**7,039.27**	**5,449.16**	**24,187.43**
II	**EXPENSES**				
	Cost of materials consumed	5,146.78	4,444.68	3,343.99	16,036.78
	Purchase of stock-in-trade	146.63	240.97	289.57	934.15
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(385.16)	271.58	79.92	(283.66)
	Employee benefits expense	440.44	392.28	374.65	1,547.48
	Finance costs	109.77	90.59	57.28	285.43
	Depreciation and amortisation expenses	256.15	235.28	177.49	791.24
	Other expenses	817.11	726.60	670.48	2,869.87
	Total Expenses	**6,531.72**	**6,401.98**	**4,993.38**	**22,181.29**
III	**Profit before Share of profit of joint venture, associate, exceptional items and tax [I-II]**	**472.15**	**637.29**	**455.78**	**2,006.14**
IV	Share of profit of joint venture and associate	4.57	5.14	5.21	19.01
V	**Profit before exceptional items and tax [III+IV]**	**476.72**	**642.43**	**460.99**	**2,025.15**
VI	Exceptional items	-	-	-	-
VII	**Profit before tax [V-VI]**	**476.72**	**642.43**	**460.99**	**2,025.15**
VIII	**Tax Expense**				
	Current tax charge	161.22	159.15	161.05	612.79
	Deferred tax charge/ (credit)	(35.45)	23.61	(36.02)	(79.77)
	Total Tax Expense	**125.77**	**182.76**	**125.03**	**533.02**
IX	**Profit after tax [VII-VIII]**	**350.95**	**459.67**	**335.96**	**1,492.13**
X	**Other comprehensive income / (loss)**				
A	Items that will not be reclassified to profit or loss				
i	Remeasurements of the defined benefit plans	0.50	11.24	(3.10)	1.86
ii	Income tax relating to items that will not be reclassified to profit or loss	(0.13)	(2.83)	0.78	(0.47)
B	Items that will be reclassified subsequently to profit or loss				
i	Exchange difference on translation of foreign operations	4.20	(2.95)	1.26	(0.84)
ii	Income tax relating to items that will be reclassified to profit or loss	(1.06)	0.74	-	0.21
	Total other comprehensive income/(loss)	**3.51**	**6.20**	**(1.06)**	**0.76**
XI	**Total comprehensive income (IX + X)**	**354.46**	**465.87**	**334.90**	**1,492.89**
	Profit for the period/year attributable to				
	Owners of the Company	350.95	459.67	335.96	1,492.13
	Non Controlling Interest	-	-	-	-
		350.95	**459.67**	**335.96**	**1,492.13**
	Other Comprehensive Income/(Loss) attributable to				
	Owners of the Company	3.51	6.20	(1.06)	0.76
	Non Controlling Interest	-	-	-	-
		3.51	**6.20**	**(1.06)**	**0.76**
	Total Comprehensive Income attributable to				
	Owners of the Company	354.46	465.87	334.90	1,492.89
	Non Controlling Interest	-	-	-	-
		354.46	**465.87**	**334.90**	**1,492.89**
	Paid up equity share capital (Face value of Rs 2.00 per share)	110.78	110.77	110.73	110.77
	Other equity				13,222.72
XII	**Earnings per equity share (in Rs.)**				
	Basic	6.34*	8.30*	6.07*	26.95
	Diluted	6.33*	8.29*	6.06*	26.93

*Not annualized

MUMBAI

ROSSARI BIOTECH LIMITED MUMBAI

Notes:

1. The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 18th July, 2026.

2. The consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) 34 on "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

3. The consolidated financial results include the financial results of four foreign subsidiaries - Rossari Global FZCO (formerly known as Rossari Global DMCC), Rossari Bangladesh Limited, Rossari International Company Limited and Rossari (Singapore) Pte Ltd (incorporated on 18th December 2025), two step-down foreign subsidiaries - Rossari Biotech Trading FZE and Unistar Thai Co. Ltd. (100% subsidiary of Rossari Global FZCO), four Indian subsidiaries - Unitop Chemicals Private Limited, Tristar Intermediates Private Limited, Buzil Rossari Private Limited and Rossari Consumer Products Private Limited, an associate company - Romakk Chemicals Private Limited and a joint venture company - Hextar Unitop SDN. BHD. (a joint venture company of Unitop Chemicals Private Limited).

4. The Group deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Group considers it as one operating segment.

5. The figures for the quarter ended 31st March, 2026 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.

6. During the quarter ended 30th June, 2026, the Parent Company has allotted 8,250 equity shares of Rs. 2 each pursuant to exercise of options under the approved Rossari Employee Stock Option Plan - 2019.

7. Previous year / period figures have been regrouped to make them comparable with the current year / period figures, wherever applicable, which are not material.

For ROSSARI BIOTECH LIMITED

ROSSARI BIOTECH LIMITED MUMBAI

EDWARD MENEZES
Executive Chairman
DIN:00149205

Place : Mumbai
Date : 18th July, 2026

WALKER CHANDIOK & CO LLP MUMBAI CHARTERED ACCOUNTANTS

Walker Chandiok & Co LLP
42nd Floor,
Building Commerz III,
International Business Park,
Oberoi Garden City,
Off Western Express Highway,
Goregaon (East),
Mumbai-400063
T +91 22 6626 2699

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Rossari Biotech Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of **Rossari Biotech Limited** ('the Company') for the quarter ended **30 June 2026**, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

Bharat Shetty
Partner
Membership No. 106815

UDIN: **26106815ULTXEB3368**

Place: Mumbai
Date: 18 July 2026

ROSSARI BIOTECH LIMITED

(An ISO 9001:2015, 14001:2015 & 45001:2018 Certified Company)
Regd. Office : Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (W) Mumbai – 400079
T +91-22-6123 3800 F +91-22- 25796982 E info@rossari.com W www.rossari.com CIN: L24100MH2009PLC194818

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026

Rs. In million

	Particulars	Quarter ended			Year Ended
		30th June, 2026	31st March, 2026	30th June, 2025	31st March, 2026
		Unaudited	Refer Note 5	Unaudited	Audited
I	**INCOME**				
	Revenue from operations	4,822.75	5,161.38	3,657.58	17,520.66
	Other Income	21.88	227.29	17.42	270.09
	Total Income	**4,844.63**	**5,388.67**	**3,675.00**	**17,790.75**
II	**EXPENSES**				
	Cost of materials consumed	2,943.94	3,288.90	2,117.43	10,664.25
	Purchase of stock-in-trade	755.51	580.43	500.84	2,384.63
	Changes in inventory of finished goods, work-in-progress and stock-in-trade	(137.44)	42.51	93.40	19.31
	Employee benefit expenses	203.87	177.52	156.66	694.62
	Finance costs	38.43	38.10	30.93	133.49
	Depreciation and amortisation expenses	83.36	89.71	71.50	309.33
	Other expenses	492.75	436.04	349.80	1,674.50
	Total Expenses	**4,380.42**	**4,653.21**	**3,320.56**	**15,880.13**
III	**Profit before exceptional items and tax [I-II]**	**464.21**	**735.46**	**354.44**	**1,910.62**
IV	Exceptional items	-	-	-	-
V	**Profit before tax [III-IV]**	**464.21**	**735.46**	**354.44**	**1,910.62**
VI	**Tax Expense**				
	Current tax charge	119.88	135.08	96.42	449.05
	Deferred tax charge/(credit)	1.67	53.08	(4.31)	33.19
	Total Tax Expense	**121.55**	**188.16**	**92.11**	**482.24**
VII	**Profit after tax [V-VI]**	**342.66**	**547.30**	**262.33**	**1,428.38**
VIII	**Other comprehensive income / (loss)**				
A	Items that will not be reclassified to profit or loss				
i	Remeasurements of the defined benefit plans	(0.16)	2.15	(0.94)	(0.66)
ii	Income tax relating to items that will not be reclassified to profit or loss	0.04	(0.54)	0.24	0.16
B	Items that will be reclassified subsequently to profit or loss	-	-	-	-
	Total other comprehensive income/(loss)	**(0.12)**	**1.61**	**(0.70)**	**(0.50)**
IX	**Total comprehensive income (VII + VIII)**	**342.54**	**548.91**	**261.63**	**1,427.88**
	Paid up equity share capital (Face value of Rs 2 per share)	110.78	110.77	110.73	110.77
	Other equity				12,074.17
X	**Earnings per equity share *(in Rs.)***				
	Basic	6.19*	9.88*	5.85*	25.79
	Diluted	6.18*	9.88*	5.84*	25.78

*Not annualized

ROSSARI BIOTECH LIMITED MUMBAI

Notes:

1. The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 18th July, 2026.

2. The standalone financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) 34 on "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

3. The Company deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Company considers it as one operating segment.

4. During the quarter ended 30th June, 2026, the Company has allotted 8,250 equity shares of Rs. 2 each pursuant to exercise of options under the approved Rossari Employee Stock Option Plan - 2019.

5. The figures for the quarter ended 31st March, 2026 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.

6. Previous year / period figures have been regrouped to make them comparable with the current year / period figures, wherever applicable, which are not material.

For ROSSARI BIOTECH LIMITED

ROSSARI BIOTECH LIMITED MUMBAI

WALKER CHANDIOK & CO LLP MUMBAI CHARTERED ACCOUNTANTS

EDWARD MENEZES
Executive Chairman
DIN:00149205

Place : Mumbai
Date : 18 July, 2026